BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38397405)

  • 1. A Challenging Correlation between Tumor Cellularity and Somatic Variant Allele Fraction in Lung and Colorectal Cancers-Specimens of Low Tumor Percentage Should Be Analyzed with Caution.
    Zarabi SK; Zhai L; Cheng YW
    Biomolecules; 2024 Jan; 14(2):. PubMed ID: 38397405
    [No Abstract]   [Full Text] [Related]  

  • 2. Implementation of next generation sequencing technology for somatic mutation detection in routine laboratory practice.
    Giardina T; Robinson C; Grieu-Iacopetta F; Millward M; Iacopetta B; Spagnolo D; Amanuel B
    Pathology; 2018 Jun; 50(4):389-401. PubMed ID: 29752127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted next-generation sequencing using fine-needle aspirates from adenocarcinomas of the lung.
    Karnes HE; Duncavage EJ; Bernadt CT
    Cancer Cytopathol; 2014 Feb; 122(2):104-13. PubMed ID: 24227699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Independent prognostic value of ultra-sensitive quantification of tumor pre-treatment T790M subclones in EGFR mutated non-small cell lung cancer (NSCLC) treated by first/second generation TKI, depends on variant allele frequency (VAF): Results of the French cooperative thoracic intergroup (IFCT) biomarkers France project.
    Beau-Faller M; Pencreach E; Leduc C; Blons H; Merlio JP; Bringuier PP; de Fraipont F; Escande F; Lemoine A; Ouafik L; Denis M; Hofman P; Lacave R; Melaabi S; Langlais A; Missy P; Morin F; Moro-Sibilot D; Barlesi F; Cadranel J;
    Lung Cancer; 2020 Feb; 140():19-26. PubMed ID: 31841714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance validation of an amplicon-based targeted next-generation sequencing assay and mutation profiling of 648 Chinese colorectal cancer patients.
    Wang Y; Liu H; Hou Y; Zhou X; Liang L; Zhang Z; Shi H; Xu S; Hu P; Zheng Z; Liu R; Tang T; Ye F; Liang Z; Bu H
    Virchows Arch; 2018 Jun; 472(6):959-968. PubMed ID: 29705968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS.
    Tuononen K; Mäki-Nevala S; Sarhadi VK; Wirtanen A; Rönty M; Salmenkivi K; Andrews JM; Telaranta-Keerie AI; Hannula S; Lagström S; Ellonen P; Knuuttila A; Knuutila S
    Genes Chromosomes Cancer; 2013 May; 52(5):503-11. PubMed ID: 23362162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR mutational genotyping of liquid based cytology samples obtained via fine needle aspiration (FNA) at endobronchial ultrasound of non-small cell lung cancer (NSCLC).
    Reynolds JP; Tubbs RR; Minca EC; MacNamara S; Almeida FA; Ma PC; Pennell NA; Cicenia JC
    Lung Cancer; 2014 Nov; 86(2):158-63. PubMed ID: 25263855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies.
    Fisher KE; Zhang L; Wang J; Smith GH; Newman S; Schneider TM; Pillai RN; Kudchadkar RR; Owonikoko TK; Ramalingam SS; Lawson DH; Delman KA; El-Rayes BF; Wilson MM; Sullivan HC; Morrison AS; Balci S; Adsay NV; Gal AA; Sica GL; Saxe DF; Mann KP; Hill CE; Khuri FR; Rossi MR
    J Mol Diagn; 2016 Mar; 18(2):299-315. PubMed ID: 26801070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FNA smears as a potential source of DNA for targeted next-generation sequencing of lung adenocarcinomas.
    Treece AL; Montgomery ND; Patel NM; Civalier CJ; Dodd LG; Gulley ML; Booker JK; Weck KE
    Cancer Cytopathol; 2016 Jun; 124(6):406-14. PubMed ID: 26882436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Major challenges related to tumor biological characteristics in accurate mutation detection of colorectal cancer by next-generation sequencing.
    Li W; Qiu T; Guo L; Ying J
    Cancer Lett; 2017 Dec; 410():92-99. PubMed ID: 28942013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges to the effectiveness of next-generation sequencing in formalin-fixed paraffin-embedded tumor samples for non-small cell lung cancer.
    da Silveira Corrêa B; De-Paris F; Viola GD; Andreis TF; Rosset C; Vianna FSL; da Rosa Rivero LF; de Oliveira FH; Ashton-Prolla P; de Souza Macedo G
    Ann Diagn Pathol; 2024 Apr; 69():152249. PubMed ID: 38150865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective.
    Aggarwal A; Sharma S; Brar Z; Kumar V; Kumar A; Katara R; Mohanty SK
    Pathol Res Pract; 2024 Jan; 253():155013. PubMed ID: 38096714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers.
    Haley L; Tseng LH; Zheng G; Dudley J; Anderson DA; Azad NS; Gocke CD; Eshleman JR; Lin MT
    Mod Pathol; 2015 Oct; 28(10):1390-9. PubMed ID: 26226847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies.
    Maus MK; Grimminger PP; Mack PC; Astrow SH; Stephens C; Zeger G; Hsiang J; Brabender J; Friedrich M; Alakus H; Hölscher AH; Lara P; Danenberg KD; Lenz HJ; Gandara DR
    Lung Cancer; 2014 Feb; 83(2):163-7. PubMed ID: 24331409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated routine workflow using next-generation sequencing and a fully-automated platform for the detection of KRAS, NRAS and BRAF mutations in formalin-fixed paraffin embedded samples with poor DNA quality in patients with colorectal carcinoma.
    Franczak C; Dubouis L; Gilson P; Husson M; Rouyer M; Demange J; Leroux A; Merlin JL; Harlé A
    PLoS One; 2019; 14(2):e0212801. PubMed ID: 30811471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Next‑generation sequencing‑based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her‑2 and TP53 mutations in patients with non‑small cell lung cancer.
    Jing C; Mao X; Wang Z; Sun K; Ma R; Wu J; Cao H
    Mol Med Rep; 2018 Aug; 18(2):2191-2197. PubMed ID: 29956783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world data of EGFR mutation testing in Chinese non-small cell carcinoma: Low tumor cell number and tumor cellularity can be accepted.
    Gu Y; Li Y; Zhao S; Jin M; Lu J; Jiang X
    Pathol Res Pract; 2022 Aug; 236():153965. PubMed ID: 35700580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Technical advance in targeted NGS analysis enables identification of lung cancer risk-associated low frequency TP53, PIK3CA, and BRAF mutations in airway epithelial cells.
    Craig DJ; Morrison T; Khuder SA; Crawford EL; Wu L; Xu J; Blomquist TM; Willey JC
    BMC Cancer; 2019 Nov; 19(1):1081. PubMed ID: 31711466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Next-Generation Sequencing, Quantitative PCR, and Sanger Sequencing for Mutation Profiling of EGFR, KRAS, PIK3CA and BRAF in Clinical Lung Tumors.
    Gao J; Wu H; Shi X; Huo Z; Zhang J; Liang Z
    Clin Lab; 2016; 62(4):689-96. PubMed ID: 27215089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of multiple gene detection with a 22-gene panel in formalin-fixed paraffin-embedded specimens of 207 colorectal cancer patients.
    Gao XH; Yu GY; Hong YG; Lian W; Chouhan H; Xu Y; Liu LJ; Bai CG; Zhang W
    Int J Clin Oncol; 2019 Feb; 24(2):141-152. PubMed ID: 30612269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.